דיפרוסאליק תרחיץ ישראל - עברית - Ministry of Health

דיפרוסאליק תרחיץ

organon pharma israel ltd., israel - betamethasone as dipropionate; salicylic acid - תרחיץ - salicylic acid 20 mg/g; betamethasone as dipropionate 0.5 mg/g - corticosteroids, potent, other combinations - provides anti-inflammatory, antipruritic, anti-allergic and keratinolytic activity in the topical management of subacute and chronic hyperkeratotic and dry dermatoses responsive to corticosteroid therapy

ולטרקס טבליות 500 מג ישראל - עברית - Ministry of Health

ולטרקס טבליות 500 מג

glaxo smith kline (israel) ltd - valaciclovir as hydrochloride - טבליות מצופות פילם - valaciclovir as hydrochloride 500 mg - valaciclovir - valaciclovir - valtrex is indicated for the treatment of herpes zoster (shingles) in immunocopotent adults.valtrex accelerates the resolution of pain, it reduces the duration, and the proportion of patients with zoster-associated pain, which includes acute and post-herpetic neuralgia. the efficacy of valaciclovir in immunocompromised patients has not been established. valtrex is indicated for the treatment of the initial and recurrent genital herpes due to herpes simplex infection. valtrex is indicated for the prevention (suppression) of recurrent herpes simplex infections (herpes genitalis). prophylaxis of cytomegalovirus infection and disease, following organ transplantation. for the treatment of cold sores (herpes labialis).

זובירקס IV ישראל - עברית - Ministry of Health

זובירקס iv

glaxo smith kline (israel) ltd - aciclovir - אבקה להכנת תמיסה לאינפוזיה - aciclovir 250 mg/vial - aciclovir - aciclovir - for the treatment of herpes simplex infections and severe initial genital herpes in the non immunocompromised. for the prophylaxis of herpes simplex infections in immune-compromised patients. in the treatment of varicella zoster infections. for herpes simplex encephalitis. for the treatment of herpes simplex infection in the neonate and infant up to 3 months of age.

רפמיון תמיסה ישראל - עברית - Ministry of Health

רפמיון תמיסה

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

פורטאו ישראל - עברית - Ministry of Health

פורטאו

eli lilly israel ltd, israel - teriparatide - תמיסה להזרקה - teriparatide 250 mcg/ml - teriparatide - teriparatide - treatment of postmenopausal women with osteoporosis at high risk for fracture:forteo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis, forteo increases bmd reduces the risk of vertebral and nonvertebral fractures . increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture :forteo is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy . treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture:forteo is indicated for the treatment of men and women with osteopo

ריזדרונט טבע   35 מג ישראל - עברית - Ministry of Health

ריזדרונט טבע 35 מג

abic marketing ltd, israel - risedronic acid as sodium - טבליה - risedronic acid as sodium 35 mg - risedronic acid - risedronic acid - treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. treatment of osteoporosis in men at high risk of fracture.

דיפרוספאן זריקה ישראל - עברית - Ministry of Health

דיפרוספאן זריקה

organon pharma israel ltd., israel - betamethasone as dipropionate; betamethasone sodium phosphate - תרחיף להזרקה - betamethasone sodium phosphate 2 mg/ml; betamethasone as dipropionate 5 mg/ml - betamethasone - betamethasone - produces anti-inflammatory, anti rheumatic and anti-allergic action and is indicated for systemic and local therapy of acute and chronic corticosteroid-responsive disorders.

זולאייר   150 מג ישראל - עברית - Ministry of Health

זולאייר 150 מג

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.

Piccolo Composite™ Plate System ישראל - עברית - Ministry of Health

piccolo composite™ plate system

קרבופיקס אורתופדיקס בע"מ - רופא - the piccolo composite™ distal fibula plates are indicated for fractures, osteotomies, and non-unions of the metaphyseal and diaphyseal region of the distal fibula, including in osteopenic bone

אנג'ליק   ישראל - עברית - Ministry of Health

אנג'ליק

bayer israel ltd - drospirenone; estradiol as hemihydrate - טבליות מצופות פילם - drospirenone 2 mg; estradiol as hemihydrate 1 mg - estradiol - estradiol - angeliq is indicated for hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women more than 1 year post menopause. prevention of postmenopausal osteoporosis in women with an increased risk of future osteoporosis fractures.